HA-Irinotecan: Phase III ongoing

Alchemia said it now expects to report top-line data from the double-blind, international Phase III ACO002 trial of HA-Irinotecan before the end of 3Q14. The company, which previously said it expected data this half, said the update is due to longer duration of PFS, which resulted in fewer events by June 30 than the company originally planned. Alchemia also said it hopes to submit regulatory submissions in the U.S. and EU in 1H15; the company previously announced a timeframe of 4Q14-1Q15. ...